Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study. by Mueller, Sabine et al.
UCSF
UC San Francisco Previously Published Works
Title
Stroke impact on mortality and psychologic morbidity within the Childhood Cancer 
Survivor Study.
Permalink
https://escholarship.org/uc/item/7nr2n50t
Authors
Mueller, Sabine
Kline, Cassie N
Buerki, Robin A
et al.
Publication Date
2019-12-06
DOI
10.1002/cncr.32612
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Cancer  Month 0, 2019
Original Article
Stroke Impact on Mortality and Psychologic Morbidity Within 
the Childhood Cancer Survivor Study
Sabine Mueller, MD, PhD, MAS1; Cassie N. Kline, MD, MAS2; Robin A. Buerki, MD, MPhil3; Yan Chen, MS4; Yutaka Yasui, PhD5; 
Rebecca Howell, PhD6; Kevin C. Oeffinger, MD7; Wendy M. Leisenring, ScD8,9; Leslie L. Robison, PhD5;  
Gregory T. Armstrong, MD, MSCE5; Heather J. Fullerton, MD2; and Kevin R. Krull, PhD 5,10
BACKGROUND: Poor socioeconomic and health-related quality of life (HRQOL) outcomes in survivors of childhood cancer can lead to 
distress and overall negatively impact the lives of these individuals. The current report has highlighted the impact of stroke and stroke 
recurrence on mortality, psychological HRQOL, and socioeconomic outcomes within the Childhood Cancer Survivor Study (CCSS). 
METHODS: The CCSS is a retrospective cohort study with longitudinal follow-up concerning survivors of pediatric cancer who were 
diagnosed between 1970 and 1986. Mortality rates per 100 person-years were calculated across 3 periods: 1) prior to stroke; 2) after 
first stroke and before recurrent stroke; and 3) after recurrent stroke. Socioeconomic outcomes, the standardized Brief Symptoms 
Inventory–18, the Medical Outcomes Study 36-Item Short Form Health Survey, and the CCSS–Neurocognitive Questionnaire also were 
assessed. RESULTS: Among 14,358 participants (median age, 39.7 years), 224 had a stroke after their cancer diagnosis (single stroke in 
161 patients and recurrent stroke in 63 patients). Based on 2636 deaths, all-cause late mortality rates were 0.70 (95% CI, 0.68-0.73) prior 
to stroke, 1.03 (95% CI, 0.73-1.46) after the first stroke, and 2.42 (95% CI, 1.48-3.94) after the recurrent stroke. Among 7304 survivors, 
those with stroke were more likely to live with a caregiver (single stroke odds ratio [OR], 2.3 [95% CI, 1.4-3.8]; and recurrent stroke OR, 
5.3 [95% CI, 1.7-16.8]) compared with stroke-free survivors. Stroke negatively impacted task efficiency (single stroke OR, 2.4 [95% CI, 
1.4-4.1] and recurrent stroke OR, 3.3 [95% CI, 1.1-10.3]) and memory (single stroke OR, 2.1 [95% CI, 1.2-3.7]; and recurrent stroke OR, 3.5 
[95% CI, 1.1-10.5]). CONCLUSIONS: Stroke and stroke recurrence are associated with increased mortality and negatively impact HRQOL 
measures in survivors of pediatric cancer. Cancer 2019;0:1-9. © 2019 American Cancer Society. 
KEYWORDS: health-related quality of life outcomes, mortality, pediatric cancer survivors, stroke, stroke recurrence.
INTRODUCTION
Given the improvements in survival in patients diagnosed with childhood cancer observed over the last 50 years, there 
are now almost 430,000 survivors in the United States.1 However, survival comes at a cost, including an increased risk of 
late (>5 years from the time of diagnosis) mortality and chronic health conditions.2,3 It is well established that survivors 
have an elevated risk of first-time and recurrent stroke compared with the general population, and this can be particularly 
heightened in patients previously exposed to radiation, such as those individuals diagnosed with brain tumors, lym-
phoma, and leukemia.4-9 Previous analyses of the Childhood Cancer Survivor Study (CCSS) cohort demonstrated that 
age-adjusted stroke rates were elevated in cancer survivors (77 per 100,000 person-years [95% CI, 62-96 per 100,000 
person-years]) compared with sibling controls (9 per 100,000 person-years [95% CI, 4-23 per 100,000 person-years]), 
with cranial radiotherapy (CRT) being a significant risk factor.7,10,11 Despite this well-documented increased stroke risk 
in survivors of pediatric cancer, to the best of our knowledge there is a paucity of data regarding how stroke and stroke 
recurrence impact mortality, psychological morbidity, and overall health-related quality of life (HRQOL) outcomes.
Multiple studies have assessed predictors of poor HRQOL in adult stroke survivors. These studies have 
indicated that initial stroke volume and location, as well as initial neurological deficits, are key determinants for poor 
HRQOL.12,13 Within the general pediatric population, young age at the time of stroke appears to have a strong influ-
ence on poor HRQOL, with the most negative impact correlating with certain periods of growth and development.14 
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In the current study, we assessed the impact of stroke and 
stroke recurrence on all-cause late mortality (>5 years 
from cancer diagnosis), as well as on multiple aspects of 
psychological and socioeconomic outcomes within the 
CCSS.
MATERIALS AND METHODS
Sample Characteristics
The CCSS is a retrospective cohort with longitudinal 
follow-up of 5-year survivors of common pediatric cancers 
including leukemia, brain tumors, Hodgkin lymphoma, 
non-Hodgkin lymphoma, bone tumors, soft-tissue sar-
comas, kidney tumors, and neuroblastoma who were 
diagnosed between January 1, 1970, and December 31, 
1999, and were aged <21 years at the time of diagnosis. 
A detailed description of the cohort has been published 
previously,15 and also is available online (www.ccss.
stjude.org). Herein, we focused analyses on the original 
cohort of survivors who were diagnosed between 1970 
and 1986 and who completed a comprehensive stroke 
survey that included questions regarding stroke recur-
rence. Appropriate institutional approval was received, 
and all participants consented prior to participation.
Data Collection
Cancer diagnosis and treatment exposures were collected 
by medical record abstraction at each participating insti-
tution. CCSS participants (or their proxy) periodically 
completed comprehensive questionnaires including infor-
mation regarding demographics, medical conditions, and 
psychological outcomes (available at www.ccss.stjude.org/
docum ents/origi nal-cohor t-quest ionna ires). Data were 
used from the baseline and multiple follow-up surveys over 
a 13-year interval, with outcomes for HRQOL, emotional 
distress, neurocognitive impairment, and social attainment 
taken from the follow-up surveys. A detailed stroke-specific 
questionnaire assessing stroke symptoms, treatment, and 
recurrence was conducted for participants who responded 
positively to a general stroke question.9 Strokes were self- 
reported and dependent on the survivor definition of 
a stroke diagnosis. Neither brain imaging nor medical 
records were available for central review. Participants who 
had missing data regarding first stroke and recurrent stroke 
were not included in the final analyses (47 participants).
Outcome Measures
Vital status, date of death, and cause of death were ascer-
tained by the National Death Index through the end of 
2013. The underlying causes of death were classified using 
the International Classification of Diseases, Ninth Revision 
(ICD-9) and ICD-10. Deaths were grouped into 3 mutually 
exclusive categories using ICD-9 and ICD-10 coding: 1) re-
currence or progression of primary cancer; 2) external causes 
(accidents, suicides, poisonings, and other external causes; 
ICD-9 codes 800-999 and ICD-10 codes V00-V99, Y00-
Y89, X00-X99, and W00-W99); and 3) health-related causes 
including subsequent neoplasms (ICD-9 codes 140-239 and 
ICD-10 codes C00-C97 and D10-D36) and cardiac (ICD-9 
codes 390-398, 402, 404, and 410-429 and ICD-10 codes 
I00-I02, I05-I09, I11, I13, I14, I20-I28, and I30-I52), pul-
monary (ICD-9 codes 460-519 and ICD-10 codes J00-J99), 
and all other medical causes. Social attainment was assessed 
through self-report of marital status, living status, and educa-
tional level. Marital status was dichotomized into “ever mar-
ried” or “never married,” with “married” defined as either 
legal marriage or living as married. Survivors aged <30 years 
were excluded from the analysis of marital status. The deci-
sion to exclude patients aged <30 years was based on the goal 
to accommodate societal trends toward older age at the time 
of marriage. We hoped to avoid an inaccurate assessment of 
single survivors who were aged <30 years and assumed to be 
unmarried due to the impact of stroke versus societal norms 
(https ://www.census.gov/data/table s/times eries/ demo/famil 
ies/marit al.html). Living status was dichotomized as living in-
dependently or not. Survivors aged <21 years were excluded 
from the analysis regarding living status. Educational attain-
ment was categorized as “less than high school,” “high school 
graduate,” or “college graduate or higher.” Survivors aged 
<25 years were excluded from the analysis of educational at-
tainment. The decision to exclude patients aged <25 years 
was based on the goal to accommodate societal trends toward 
older age at the time of completion of educational attainment. 
We hoped to avoid an inaccurate assessment of lower educa-
tional attainment due to the impact of stroke versus societal 
norms (https ://nces.ed.gov/fastf acts/displ ay.asp?xml:id=27). 
Employment status was categorized into “employed,” “un-
employed, but seeking work,” or “unable to work.”
The Medical Outcomes Study 36-Item Short Form 
Health Survey (SF-36) assessed HRQOL and comprises 8 
domains: 1) physical functioning; 2) role limitations result-
ing from physical health problems; 3) bodily pain; 4) gen-
eral health perceptions; 5) vitality; 6) social functioning; 
7) role limitations resulting from emotional problems; and 
8) mental health.16 Domain scores were converted to T 
scores (mean, 50; SD, 10), with T scores ≤40 classified as 
impaired, consistent with the scoring manual.
The CCSS–Neurocognitive Questionnaire (NCQ) is 
a 25-item questionnaire that assessed 4 neurocognitive do-
mains: 1) task efficiency; 2) emotional regulation; 3) organi-
zation; and 4) memory.17 Domain scores for each participant 
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are calculated using a 3-point Likert scale with a range of 1 
(“never a problem”) to 3 (“often a problem”). These scores 
were compared with normative data to generate T scores, 
with participants with scores ≥63 classified as impaired.
The Brief Symptom Inventory 18 (BSI-18) mea-
sured emotional distress and has been validated previ-
ously in cancer survivors.18 The BSI-18 classifies distress 
into 3 symptom scales: 1) anxiety (6 items); 2) depres-
sion (6 items); and 3) somatization (6 items). For each 
item, a 5-point Likert scale with a range of 1 (“not at all”) 
to 5 (“extremely”) is used to identify the degree to which 
symptoms were bothersome during the 7 days prior to 
test administration. The scale scores were compared 
with normative data to generate T scores, with partic-
ipants with scores ≥63 classified as impaired. Survivors 
aged <18 years were excluded from BSI-18 analysis.
Statistical Analysis
Demographic and treatment characteristics of the survi-
vors were tabulated and compared between CNS cancer 
and non-CNS cancer using chi-square tests. Mortality 
rates per 100 person-years starting from 5 years after the 
cancer diagnosis were estimated across 3 time periods: 1) 
prior to stroke (stroke free); 2) after the first stroke but 
before the recurrent stroke (after stroke); and (3) after the 
recurrent stroke. The follow-up period ended at the date 
of death or December 31, 2013, whichever came first. 
Cox regression analysis was used to assess the association 
between stroke and all-cause mortality hazard rates and 
health-related cause-specific mortality hazard rates, using 
age as the time scale, comparing the periods after stroke 
and after recurrent stroke with the stroke-free period, ad-
justing for sex, age at the time of diagnosis, and cardio-
vascular risk factors including hypertension and diabetes 
as well as hypercholesteremia (if reported to be >grade 
1) (National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.03 Grade>1).
Associations between stroke and neurocognitive im-
pairment, HRQOL, emotional distress, and social attain-
ment were assessed using multivariable logistic regression, 
adjusting for sex, age at the time of diagnosis, age at the 
time of the survey, maximum cumulative CRT dose, and 
cumulative intrathecal (IT) and cumulative intravenous 
(iv) dose of methotrexate. Multivariable polytomous logis-
tic regression was used for educational attainment and em-
ployment outcomes, stratified by survivors of CNS cancer 
and survivors of non-CNS cancer. The same adjustment 
variables were used for each group of survivors, with the 
exception of cumulative IT dose and cumulative iv dose 
of methotrexate for the cohort of survivors of CNS cancer.
RESULTS
Association Between Stroke and All-Cause  
and Health-Related Mortality
There were 14,358 survivors diagnosed with cancer be-
tween 1970 and 1986 and who completed the CCSS 
baseline questionnaire (Table 1). At a median follow-up 
of 32 years (range, 5-44 years) from diagnosis, there were 
2664 deaths reported from all causes (Supporting Table 1 
lists cause-specific deaths). Occurrence of stroke was re-
ported among a total of 224 survivors (161 with a single 
stroke and 63 with a recurrent stroke), 48 of whom were 
deceased (32 after a single stroke and 16 after a recurrent 
stroke) at the time of follow-up. No patient reported a 
history of stroke prior to their cancer diagnosis. The cor-
responding late mortality rate (MR) per 100 person-years 
was 0.70 (95% CI, 0.68-0.73) in the stroke-free time 
period, 1.03 (95% CI, 0.73-1.46) in the post-stroke period, 
and 2.42 (95% CI, 1.48-3.94) in the post–recurrent stroke 
period (Tables 2 and 3). A history of single and recurrent 
stroke was associated with an increase in the late mortal-
ity hazard ratio (HR) compared with the stroke-free period 
(single stroke HR, 1.46 [95% CI, 1.03-2.07; P = .04] and 
recurrent stroke HR, 3.45 [95% CI, 2.11-5.65; P < .001]).
Among 1844 survivors of CNS tumors, 467 died 
prior to any reported stroke, whereas 87 survivors re-
ported at least 1 stroke (Tables 2 and 3). The late MR 
per 100 person-years was 1.07 (95% CI, 0.98-1.17) in 
the prestroke period, 1.32 (95% CI, 0.78-2.23) in the 
post–single stroke period, and 1.44 (95% CI, 0.60-3.45) 
in the post–recurrent stroke period.
Among 12,467 survivors of non-CNS tumors, a 
total of 2121 died prior to any reported stroke, whereas 
137 reported at least 1 stroke (Tables 2 and 3). There 
was a significantly increased MR noted in the post– 
recurrent stroke period of 3.50 per 100 person-years 
(95% CI, 1.94-6.33). Survivors of non-CNS tumors 
with a history of stroke recurrence had an increased HR 
for all-cause late mortality (HR, 4.77; 95% CI, 2.64-8.65 
[P < .001]). This increase appeared to be driven by sur-
vivors of leukemia, in whom the all-cause late mortality 
HR increased by >10-fold in the recurrent stroke setting 
(HR, 10.90; 95% CI, 4.87-24.42 [P < .001]) (Table 2).
When specifically assessing health-related late mortal-
ity among survivors of childhood cancer, stroke was found 
to have a similar impact compared with all-cause mortality 
(Table 3). Survivors with a history of stroke demonstrated 
an increased cause-specific hazard rate for health-related 
late mortality (HR, 2.11; 95% CI, 1.40-3.20 [P ≤ .001]), 
which was further increased by the presence of recurrent 
stroke (HR, 4.98; 95% CI, 2.87-8.63 [P < .001]).
Original Article
4 Cancer  Month 0, 2019
Association Between Stroke and Psychological 
Morbidity and Social Attainment
Of the overall cohort, a total of 7304 survivors of child-
hood cancer completed psychological and social ques-
tionnaires during follow-up. Occurrence of stroke was 
reported in a total of 122 of the survivors who com-
pleted psychological and social questionnaires (103 
with a single stroke and 19 with a recurrent stroke). The 
median time between the most recently reported stroke 
and the psychosocial assessments was 16.2 years (range, 
0-36.2  years). Respondents included 900 survivors of 
CNS cancer and 6404 survivors of non-CNS cancer. 
The CRT dose was higher in survivors of CNS cancer 
compared with survivors of non-CNS cancer (P < .001) 
(see Supporting Table 2). Survivors of childhood cancer 
with history of stroke also were more likely to report 
a history of hypertension (P <  .001) (see Supporting 
Table 2) and hypercholesterolemia (P  =  .003) (see 
Supporting Table 2).
A total of 3095 survivors for whom information re-
garding stroke was available, including no stroke history, 
were excluded from the analysis of marriage outcomes 
TABLE 1. Demographic And Treatment Characteristics and Vital Status of Survivors of Childhood Cancer
Characteristic
All Diagnoses N = 14,358 
N = 14,358 (%)
With Strokea 
N = 224 (%)
No Stroke 
N = 14,087 (%) P
Vital status       .24
Alive 11,694 (81.4%) 176 (78.60%) 11,499 (81.6%)  
Dead 2664 (18.6%) 48 (21.4%) 2588 (18.4%)  
Sex       .75
Male 7713 (53.7%) 118 (52.7%) 7573 (53.8%)  
Female 6645 (46.3%) 106 (47.3%) 6514 (46.2%)  
Race       .37
White, non-Hispanic 12,397 (86.3%) 194 (86.6%) 12,162 (86.3%)  
Black, non-Hispanic 694 (4.8%) 12 (5.4%) 678 (4.8%)  
Hispanic/Latino 750 (5.2%) 7 (3.1%) 741 (5.3%)  
Other 517 (3.6%) 11 (4.9%) 506 (3.6%)  
Mean age at baseline survey (SD), y 24 (7.8) 24 (7.8) 24 (7.8) .63
Mean age at cancer diagnosis (SD), y 8 (5.8) 9 (5.7) 8 (5.8) .23
Age at end of follow-up period (SD), y 39 (9.7) 40 (10.2) 39 (9.7) .69
Mean y from diagnosis to death (SD) 31 (8.2) 31 (8.0) 31 (8.2) .69
Mean age at confirmed first stroke (SD), y   21.3 (13.7)    
Mean age at second stroke (SD), y   29.0 (13.8)    
Maximum cranial radiation, Gyb       <.001
No CRT 4135 (33.6%) 40 (19.6%) 4090 (33.9%)  
<20 5200 (42.2%) 52 (25.5%) 5142 (42.6%)  
20 to <30 1464 (11.9%) 27 (13.2%) 1436 (11.9%)  
30 to <40 158 (1.3%) 3 (1.5%) 154 (1.3%)  
40 to <50 341 (2.8%) 10 (4.9%) 327 (2.7%)  
≥50 1026 (8.3%) 72 (35.3%) 933 (7.7%)  
Cumulative IT doseb       .81
None 7872 (65.3%) 139 (67.1%) 7694 (65.2%)  
<200 mg/m2 2318 (19.2%) 39 (18.8%) 2277 (19.3%)  
≥200 mg/m2 1859 (15.4%) 29 (14.0%) 1829 (15.5%)  
Cumulative iv methotrexate doseb       .05
None 9947 (81.0%) 180 (87.4%) 9727 (80.8%)  
<5000 mg/m2 1454 (11.8%) 18 (8.7%) 1433 (11.9%)  
≥5000 mg/m2 886 (7.2%) 8 (3.9%) 878 (7.3%)  
Smoking status at baselineb       .27
Current smoker 1817 (12.9%) 23 (10.4%) 1791 (13.0%)  
Former smoker 1080 (7.7%) 13 (5.9%) 1064 (7.7%)  
Never smoker 11,197 (79.5%) 186 (83.8%) 10,972 (79.4%)  
Hypertension       <.001
Yes 2171 (15.1%) 74 (33.0%) 2086 (14.8%)  
No 12,186 (84.9%) 150 (67.0%) 12,001 (85.2%)  
Diabetes       .26
Yes 726 (5.1%) 15 (6.7%) 707 (5.0%)  
No 13,631 (94.9%) 209 (93.3%) 13,380 (95.0%)  
Hypercholesteremia       <.001
Yes 1606 (11.2%) 64 (28.6%) 1533 (10.9%)  
No 12,751 (88.8%) 160 (71.4%) 12,554 (89.1%)  
Abbreviations: CRT, cranial radiotherapy; Gy, Gray; IT, intrathecal; iv, intravenous.
aA total of 47 survivors with missing stroke dates were excluded.
bPercentages for individual characteristics were calculated based on the total number of participants for whom information was available.
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based on an age of <30 years at the time of analysis. The 
remaining survivors with a history of a single stroke were 
less likely to be married (odds ratio [OR], 0.5; 95% CI, 
0.3-0.95 [P =  .04]) compared with survivors with no 
stroke history (Table 4).
Survivors with a history of a single stroke (95 sur-
vivors; OR, 2.3 [95% CI, 1.4-3.8; P =  .002]) or recur-
rent stroke (18 survivors; OR, 5.3 [95% CI, 1.7-16.8; 
P = .005]) were more likely to be living with a caregiver 
compared with stroke-free survivors. Stroke history was 
found to be associated with an elevated risk of an inabil-
ity to work rather than being employed, and this risk tri-
pled between survivors with single and recurrent strokes 
(OR for single stroke, 3.2 [95% CI, 1.8-5.7; P < .001]; 
and OR for recurrent stroke, 9.5 [95% CI, 3.2-27.9; 
P < .001]) (Table 5). It is important to note that survi-
vors who experienced a second stroke were much more 
likely to report “no recovery” from the stroke (first stroke 
TABLE 2. Stroke and All-Cause Mortality in Survivors of Childhood Cancer Overall and by Primary Cancer 
Diagnosisa 
Cancer Type No. of Strokes No. of Deaths Populationa Person-Years
Late MRb Late Mortality HRb,c 
MR 95% CI HR 95% CI P
Any No stroke 2588 14,087 368,720 0.70 0.68-0.73 Referent    
  Single stroke 32 161 3095 1.03 0.73-1.46 1.46 1.03-2.07 .04
  Recurrent stroke 16 63 662 2.42 1.48-3.94 3.45 2.11-5.65 <.001
CNS No stroke 467 1757 43,526 1.07 0.98-1.17 Referent    
  Single stroke 14 54 1062 1.32 0.78-2.23 1.31 0.77-2.23 .32
  Recurrent stroke 5 33 348 1.44 0.60-3.45 1.42 0.58-3.47 .44
Other than CNS No stroke 2121 12,330 325,194 0.65 0.63-0.68 Referent    
  Single stroke 18 107 2033 0.89 0.56-1.41 1.24 0.78-1.97 .37
  Recurrent stroke 11 30 314 3.50 1.94-6.33 4.77 2.64-8.65 <.001
Leukemia No stroke 683 4753 122,832 0.56 0.52-0.60 Referent    
  Single stroke 7 60 1224 0.57 0.27-1.20 0.99 0.47-2.10 .98
  Recurrent stroke 6 12 125 4.81 2.16-10.70 10.90 4.87-24.42 <.001
HL No stroke 607 1903 49,634 1.22 1.13-1.32 Referent    
  Single stroke 4 16 222 1.80 0.68-4.80 1.01 0.38-2.74 .98
  Recurrent stroke 1 5 32 3.08 0.43-21.89 1.33 0.18-9.60 .78
Abbreviations: CNS, central nervous system; HL, Hodgkin lymphoma; HR, hazard ratio; MR, mortality rate.
aThe sum of the population was not 14,358 because of missing information regarding stroke in 47 patients.
bBold type indicates statistical significance.
cModel was adjusted for sex, age at the time of diagnosis, and cardiovascular risk factor >grade 1 including hypertension, diabetes, and hypercholesterolemia.
TABLE 3. Stroke and Health-Related Mortality in Survivors of Childhood Cancer Overall and by Primary 
Cancer Diagnosis
Cancer Type No. of Strokes No. of Deaths Populationa Person-Years
Late MRb Late Mortality HRb,c 
MR 95% CI HR 95% CI P
Any No stroke 1159 14,087 368,720 0.31 0.30-0.33 Referent    
  Single stroke 23 161 3095 0.74 0.49-1.12 2.11 1.40-3.20 <.001
  Recurrent stroke 13 63 662 1.96 1.14-3.38 4.98 2.87-8.63 <.001
CNS No stroke 204 1757 43,526 0.47 0.41-0.54 Referent    
  Single stroke 2 54 1062 1.04 0.57-1.87 2.10 1.14-3.87 .02
Other than CNS No stroke 955 12,330 325,194 0.29 0.28-0.31 Referent    
  Single stroke 12 107 2033 0.59 0.34-1.04 1.62 0.92-2.88 .10
  Recurrent stroke 8 30 314 2.55 1.27-5.09 6.06 3.01-12.20 <.001
Leukemia No stroke 224 4753 122,832 0.18 0.16-0.21 Referent    
  Single stroke 2 60 1224 0.16 0.04-0.65 0.77 0.19-3.10 .71
  Recurrent stroke 4 12 125 3.20 1.20-8.54 16.14 5.94-43.84 <.001
HL No stroke 347 1903 49,634 0.70 0.63-0.78 Referent    
  Single stroke 4 16 222 1.80 0.68-4.80 1.77 0.65-4.83 .26
  Recurrent stroke 1 5 32 3.08 0.43-21.89 2.57 0.35-18.64 .35
Abbreviations: CNS, central nervous system; HL, Hodgkin lymphoma; HR, hazard ratio; MR, mortality rate.
aThe sum of the population was not 14,358 because of missing information regarding stroke in 47 patients.
bBold type indicates statistical significance.
cModel was adjusted for sex, age at the time of diagnosis, and cardiovascular risk factor >grade 1 (National Cancer Institute Common Terminology Criteria for 
Adverse Events version 4.03 Grade>1) including hypertension, diabetes, and hypercholesterolemia.
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rate of no recovery of 8.86% vs second stroke rate of no 
recovery of 26.3%). A total of 1580 survivors for whom 
information regarding stroke was available, including no 
stroke history, were excluded from the analysis of educa-
tional outcomes based on an age <25 years at the time of 
analysis. For survivors of CNS tumors, a history of stroke 
was associated with increased odds of having attained less 
than a high school education compared with achieving a 
college education or higher (OR, 4.0; 95% CI, 1.2-13.7 
[P = .03]) (see Supporting Table 3).
Adjusting for relevant treatment exposures, survi-
vors who reported a history of strokes had more problems 
with task efficiency (OR for a single stroke, 2.4 [95% 
CI, 1.4-4.1; P < .001]; and OR for recurrent stroke, 3.3 
[95% CI, 1.1-10.3; P = .04]), emotional regulation (OR 
for recurrent stroke, 3.6 [95% CI, 1.2-11.2; P =  .03]), 
and memory (OR for a single stroke, 2.1 [95% CI, 1.2-
3.7; P = .009]; and OR for a recurrent stroke, 3.5 [95% 
CI, 1.1-10.5; P =  .03]) compared with those without a 
history of stroke (Table 6). Survivors with a stroke history 
reported reduced HRQOL in terms of physical function-
ing compared with those without a stroke history (OR for 
a single stroke, 3.1 [95% CI, 1.8-5.3; P < .001]; and OR 
for recurrent stroke, 11.0 [95% CI, 3.7-32.5; P < .001]). 
An increased prevalence of depressive symptoms was ob-
served in survivors with recurrent stroke compared with 
those with a single stroke (43.8% vs 11.3%; OR, 4.9 
[95% CI, 1.7-13.9; P = .003]).
DISCUSSION
Survivors of pediatric cancer are at an increased risk of 
stroke. The results of the current study demonstrated to 
the best of our knowledge for the first time that, when 
stroke does occur, survivors are at an increased risk of 
both all-cause and health-related mortality and are nega-
tively impacted across the domains of social attainment, 
HRQOL, neurocognitive function, and emotional dis-
tress. Overall, all-cause mortality as well as health-related 
TABLE 4. Association Between Stroke and Social Attainment in Survivors of Childhood Cancera 
  Stroke Total Yes No. (%) No No. (%)
ORb (95% CI) 
(Yes Vs No)c Pc 
Ever married None 4080 3008 (73.7) 1072 (26.3)    
Single 67 37 (55.2) 30 (44.8) 0.5 (0.3-1.0) .04
Recurrent 8 6 (75.0) 2 (25.0) 1.3 (0.2-7.0) .75
Living with a caregiver None 6707 1530 (22.8) 5177 (77.1)    
Single 95 40 (42.1) 55 (57.9) 2.3 (1.4-3.8) .002
Recurrent 18 11 (61.1) 7 (38.9) 5.3 (1.7-16.8) .005
Abbreviation: OR, odds ratio.
aExcluding survivors who were aged <30 years for outcome regarding ever married and survivors who were aged <21 years for outcome regarding independent 
living.
bThe OR was adjusted for sex, age at the time of diagnosis, age at the time of the survey, maximum cranial radiotherapy dose, cumulative intrathecal dose, and 
cumulative intravenous methotrexate dose.
cBold type indicates statistical significance.
TABLE 5. Association Between Stroke and Employment Status, Overall and by Cancer Type in Survivors of 
Childhood Cancer
Diagnosis Stroke Total
Employed 
No. (%)
Unemployed 
No. (%)
Unable to 
Work No. (%)
Unemployed Vs 
Employed
Unable to Work Vs 
Employed
ORa 
(95% CI)b Pb 
ORa 
(95% CI)b Pb 
Any cancer type None 7077 6314 (89.2) 341 (4.8) 422 (6.0) 1.0   1.0  
Single 100 72 (72.0) 5 (5.00) 23 (23.0) 1.2 (0.5-3.1) .67 3.2 (1.8-5.7) <.001
Recurrent 19 10 (52.6) 1 (5.26) 8 (42.1) 1.5 (0.2-12.1) .72 9.5 (3.2-27.9) <.001
CNS None 822 632 (76.9) 67 (8.2) 123 (15.0) 1.0   1.0  
Single 32 17 (53.1) 3 (9.4) 12 (37.5) 1.6 (0.4-5.7) .49 4.1 (1.8-9.3) <.001
Recurrent 10 3 (30.0) 1 (10.0) 6 (60.0) 3.2 (0.3-33) .33 12.7 (2.7-59.4) .001
Other than CNS None 6255 5682 (90.8) 274 (4.4) 299 (4.8) 1.0   1.0  
Single 68 55 (80.9) 2 (2.9) 11 (16.2) 0.9 (0.2-3.9) .91 2.6 (1.1-6.3) .03
Recurrent 9 7 (77.8) 0 (0.0) 2 (22.2) 0.0 (0.0->999) .97 8.0 (1.6-40.5) .01
Abbreviations: CNS, central nervous system; OR, odds ratio.
aThe OR was adjusted for sex, age at the time of diagnosis, age at the time of the survey, maximum cranial radiotherapy dose, cumulative intrathecal dose, and 
cumulative intravenous methotrexate dose for survivors of non-CNS tumors; for survivors of CNS tumors, the OR was adjusted for sex, age at the time of diagnosis, 
age at the time of the survey, and maximum cranial radiation dose.
bBold type indicates statistical significance.
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mortality increased by >3-fold in cancer survivors who 
experienced repeated strokes compared with those with 
no stroke history. Conversely, overall stroke-related mor-
tality in the average adult population has appeared to be 
decreasing in recent decades, which appears to be diver-
gent to stroke-related mortality in survivors of pediatric 
cancer.19 Stroke risk in survivors of pediatric cancer has 
been associated previously with dose-dependent exposure 
to CRT.10 It is interesting to note that the majority of the 
patient population in the current study did not receive 
CRT or received only low-dose exposure (<20 grays) as 
may be expected in survivors of leukemia or non-CNS 
solid tumors. Survivors of CNS tumors did not have a 
significantly greater risk of all-cause mortality after stroke 
or recurrent stroke. This may be attributable to the fact 
that the reference group, survivors of CNS tumors with-
out a history of stroke, already have an elevated risk of 
mortality.2 Regardless, recommendations to screen and 
TABLE 6. Association Between Stroke and Neurocognitive Function and HRQOL in Survivors of Pediatric 
Cancer (N = 7304)
  Variable Stroke Total Yes No. (%) No No. (%) ORa (95% CI)b Pb 
NCQ Task efficiency None 5917 1399 (23.6) 4518 (76.4) 1.0  
Single 81 42 (51.9) 39 (48.2) 2.4 (1.4-4.1) <.001
Recurrent 15 9 (60.0) 6 (40.0) 3.3 (1.1-10.3) .04
Emotional regulation None 5921 746 (12.6) 5175 (87.4) 1.0  
Single 82 13 (15.9) 69 (84.2) 1.1 (0.6-2.3) .70
Recurrent 15 6 (40.0) 9 (60.0) 3.6 (1.2-11.2) .03
Organization None 5923 777 (13.1) 5146 (86.9) 1.0  
Single 81 15 (18.5) 66 (81.5) 1.0 (0.5-2.0) .92
Recurrent 15 4 (26.7) 11 (73.3) 2.2 (0.7-7.3) .19
Memory None 5923 840 (14.2) 5083 (85.8) 1.0  
Single 82 21 (25.6) 61 (74.4) 2.1 (1.2-3.7) .009
Recurrent 15 6 (40. 0) 9 (60.0) 3.5 (1.1-10.5) .03
SF-36 Physical function None 6141 712 (11.6) 5429 (88.4) 1.0  
Single 89 27 (30.3) 62 (69.7) 3.1 (1.8-5.3) <.001
Recurrent 16 9 (56.3) 7 (43.8) 11.0 (3.7-32.5) <.001
Role limitations–physical None 6120 806 (13.2) 5314 (86.8) 1.0  
Single 87 21 (24.1) 66 (75.9) 1.9 (1.1-3.3) .03
Recurrent 16 7 (43.8) 9 (56.3) 3.9 (1.4-11.3) .01
Bodily pain None 6134 1125 (18.3) 5009 (81.7) 1.0  
Single 88 29 (33.0) 59 (67.1) 2.0 (1.2-3.4) .008
Recurrent 16 6 (37.5) 10 (62.5) 3.1 (1.1-8.9) .04
General health None 5986 1366 (22.8) 4620 (77.2) 1.0  
Single 86 30 (34.9) 56 (65.1) 1.4 (0.9-2.4) .17
Recurrent 16 9 (56.3) 7 (43.6) 3.9 (1.4-11.0) .01
Vitality None 5998 1465 (24.4) 4533 (75.6) 1.0  
Single 84 24 (28.6) 60 (71.4) 1.3 (0.8-2.3) .32
Recurrent 16 6 (37.5) 10 (62.5) 1.5 (0.5-4.6) .43
Role limitations–emotional None 6106 1092 (17.9) 5014 (82.1) 1.0  
Single 87 16 (18.4) 71 (81.6) 0.9 (0.5-1.8) .84
Recurrent 16 4 (25.0) 12 (75.0) 1.1 (0.3-4.1) .85
Social function None 6150 820 (13.3) 5330 (86.7)    
Single 88 12 (13.6) 76 (86.4) 1.1 (0.6-2.1) .77
Recurrent 16 7 (43.8) 9 (56.3) 4.1 (1.4-11.6) .009
Mental health None 5998 1082 (18.0) 4916 (82.0)    
Single 84 17 (20.2) 67 (79.8) 1.2 (0.6-2.1) .60
Recurrent 16 3 (18.8) 13 (81.3) 0.7 (0.1-2.9) .59
BSI-18c Depression None 6153 692 (11.3) 5461 (88.8)    
    Single 86 8 (9.3) 78 (90.7) 0.9 (0.4-1.9) .69
    Recurrent 16 7 (43.8) 9 (56.3) 4.9 (1.7-13.9) .003
  Anxiety None 6153 440 (7.2) 5713 (92.9)    
    Single 86 7 (8.1) 79 (91.9) 1.3 (0.5-2.9) .60
    Recurrent 16 3 (18.8) 13 (81.3) 1.9 (0.4-8.6) .40
  Somatization None 6151 801 (13.0) 5350 (87.0)    
    Single 86 14 (16.3) 72 (83.7) 1.1 (0.5-2.2) .85
    Recurrent 16 3 (18.8) 13 (81.3) 1.8 (0.5-6.5) .37
Abbreviations: BSI-18, Brief Symptom Inventory-18; HRQOL, health-related quality of life; NCQ, Childhood Cancer Survivor Study–Neurocognitive Questionnaire; 
OR, odds ratio; SF-36, Medical Outcomes Study 36-Item Short Form Health Survey.
aThe OR was adjusted for sex, age at the time of diagnosis, age at the time of the survey, maximum cranial radiotherapy dose, cumulative intrathecal dose, and 
cumulative intravenous methotrexate dose.
bBold type indicates statistical significance.
cSurvivors who were aged <18 years were excluded.
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potentially intervene with regard to stroke risk in survi-
vors of pediatric cancer might need to be implemented 
more aggressively. The data from the current study sup-
port close screening and potential aggressive interventions 
when possible.10 We have highlighted the negative impact 
stroke has on HRQOL, neurocognition, emotional well-
being, and socioeconomic achievement beyond the risk 
associated with CRT exposure and neurotoxic chemo-
therapies. This was magnified further within the setting 
of recurrent stroke. Specifically, the odds of reporting 
poorer physical function in HRQOL more than tripled 
when survivors experienced a recurrent stroke compared 
with those with a single stroke. The odds of reporting 
lower scores on HRQOL related to social function also 
quadrupled when comparing those with a history of re-
current strokes with those with a history of a single stroke. 
Survivors with a stroke history were less likely to be mar-
ried and to progress to postsecondary education, and were 
more likely to be unemployed or unable to work and more 
likely to fail to achieve independent living compared with 
their counterparts without a stroke history. Previous stud-
ies have shown that survivors of childhood cancer who 
demonstrated lower neurocognitive outcomes also dem-
onstrated worse HRQOL,20,21 and were more likely to be 
economically dependent and to demonstrate lower earning 
ability, and stroke appears to contribute to these risks.22-
24 These previously established risks combined with the 
newly demonstrated overall increased negative impact 
of stroke and stroke recurrence on HRQOL and long-
term morbidity in survivors of pediatric cancer25 iden-
tify a high-risk population. Presumably, the link between 
stroke and these long-term outcomes is a combined effect 
of stroke-related neurocognitive injury, ongoing medical 
management in the poststroke period, and the burden of 
a new life-threatening event in a patient who already has 
experienced one life-threatening diagnosis, among other 
stressors. The former explanations also would be in line 
with reports of lower QOL measures among adults with 
a history of stroke, unrelated to a prior history of can-
cer.26,27 However, larger prospective studies are needed to 
more completely isolate the etiology of why such a high 
percentage of survivors of pediatric cancer who experience 
stroke go on to develop negative HRQOL and psychoso-
cial outcomes.
One key limitation of the current study was the self-re-
ported nature of patient medical history, including stroke 
history and cancer recurrence. Patient self-report could be 
derived from self-perceived symptoms, physician-derived 
diagnoses, and/or imaging reports. Self-reported out-
comes may introduce bias by including both false-positive 
results, such as focal neurologic stroke-like events (as in 
transient ischemic attack, nonconvulsive seizure, or hemi-
plegic migraine) that are unconfirmed by a physician, and 
false-negative findings, such as subclinical strokes that are 
undetected by patients or not evident to their clinicians. 
The standard outcome measure of stroke-related morbid-
ity is the modified Rankin Scale, which is not captured 
within the CCSS survey. The self-reported HRQOL vari-
ables of “physical function” and “physical limitations” were 
not corroborated by neurological or clinical examinations. 
Thus, stroke-related morbidity outcomes can be con-
cluded from CCSS data, but we were unable to precisely 
attribute a clinically meaningful severity to self-reported 
physical limitations. In addition, the reporting of the 
occurrence of a recurrent or second stroke also may include 
recrudescence of incident stroke symptoms rather than a 
new, separate event. It also is conceivable that symptoms 
of a stroke mimic recurrent cancer; given the nature of the 
self-reported data collection, we were unable to assess a re-
liable association between stroke and cancer recurrence. As 
is true in other self-reported questionnaire-based studies, 
there is the possibility of participation and recall biases, 
degrading data from both the survivor population and sib-
ling control cohort population.2
Because incident stroke correlates with poorer 
HRQOL measures, there may be an indication to in-
tervene sooner and more aggressively to prevent stroke 
in these survivors. Tighter control of modifiable stroke 
risk factors (eg, hyperlipidemia and hypertension) and 
antithrombotic therapies for primary and secondary 
stroke prevention may be warranted in this population.10 
Survivors who have experienced stroke may require 
additional support services to allay the negative impact of 
stroke on physical, neurocognitive, and emotional health 
to help these patients achieve higher rates of employment 
and independent living. As we continue to improve ther-
apy for pediatric cancer patients and increase survivor-
ship, it will be paramount for both pediatric and adult 
practitioners to identify those tumor survivors at greatest 
risk of poor long-term outcomes and low HRQOL.
FUNDING SUPPORT
Supported by the National Cancer Institute (grant U24 CA 55727 to 
Gregory T. Armstrong), the Cancer Center Support (CORE) (grant 
CA21765 to C. Roberts), and the American Lebanese Syrian Associated 
Charities (ALSAC). Sabine Mueller and Heather J. Fullerton were sup-
ported by the LaRoche family. Cassie N. Kline was supported by the Frank 
A. Campini Foundation, the Cannonball Kids’ Cancer Foundation (grant 
A129749), and the National Center for Advancing Translational Sciences 
of the National Institutes of Health (grant KL2TR001870). This content is 
solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. The study sponsors had 
no impact on study design and data analysis.
Stroke Impact on Mortality and HRQOL/Mueller et al
9Cancer  Month 0, 2019
CONFLICT OF INTEREST DISCLOSURES
Wendy M. Leisenring has received grants from the National Institutes of 
Health for work performed as part of the current study. Kevin R. Krull has 
received grants from the National Cancer Institute for work performed as 
part of the current study. The other authors made no disclosures.
AUTHOR CONTRIBUTIONS
Sabine Mueller: Design and interpretation of the data and drafting of the 
article. Cassie N. Kline: Analysis and interpretation of the data and draft-
ing of the article. Robin A. Buerki: Analysis and interpretation of the data 
and drafting of the article. Yan Chen: Design and interpretation of the data 
and drafting of the article. Yutaka Yasui: Design and interpretation of the 
data and drafting of the article. Rebecca Howell: Design and interpretation 
of the data and drafting of the article. Kevin C. Oeffinger: Design and 
interpretation of the data and drafting of the article. Wendy M. Leisenring: 
Design and interpretation of the data and drafting of the article. Leslie L. 
Robison: Design and interpretation of the data and drafting of the article. 
Gregory T. Armstrong: Design and interpretation of the data and drafting 
of the article. Heather J. Fullerton: Design and interpretation of the data 
and drafting of the article. Kevin R. Krull: Design and interpretation of the 
data and drafting of the article.
REFERENCES
 1. Noone AM, Howlader N, Krapcho M, et al, eds. SEER Cancer 
Statistics Review, 1975-2015. National Cancer Institute; 2018; based 
on November 2017 SEER data submission.
 2. Armstrong GT, Yasui Y, Robison LL. Reduction in late mortality after 
childhood cancer. N Engl J Med. 2016;375:290-292.
 3. Gibson TM, Mostoufi-Moab S, Stratton KL, et al. Temporal patterns 
in the risk of chronic health conditions in survivors of childhood can-
cer diagnosed 1970-99: a report from the Childhood Cancer Survivor 
Study cohort. Lancet Oncol. 2018;19:1590-1601.
 4. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of 
Hodgkin's disease: a report from the Childhood Cancer Survivor Study. 
J Clin Oncol. 2005;23:6508-6515.
 5. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among 
long-term survivors of childhood leukemia and brain tumors: a 
report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006; 
24:5277-5282.
 6. Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation in-
creases risk of stroke in pediatric brain tumor survivors. Stroke. 
2012;43:3035-3040.
 7. Mueller S, Fullerton HJ, Stratton K, et al. Radiation, atherosclerotic 
risk factors, and stroke risk in survivors of pediatric cancer: a report 
from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol 
Phys. 2013;86:649-655.
 8. Mueller SS, K, Hills NK, Chettour N, et al. Risk of stroke and stroke 
recurrence in pediatric cancer survivors treated with cranial radiation 
therapy. Int J Radiat Oncol Biol Phys. 2013;86:643-648.
 9. Fullerton HJ, Stratton K, Mueller S, et al. Recurrent stroke in child-
hood cancer survivors. Neurology. 2015;85:1056-1064.
 10. Mueller S, Sear K, Hills NK, et al. Risk of first and recurrent stroke in 
childhood cancer survivors treated with cranial and cervical radiation 
therapy. Int J Radiat Oncol Biol Phys. 2013;86:643-648.
 11. Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya follow-
ing cranial irradiation for primary brain tumors in children. Neurology. 
2007;68:932-938.
 12. Christensen MC, Mayer S, Ferran JM. Quality of life after intracerebral 
hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke 
(FAST) trial. Stroke. 2009;40:1677-1682.
 13. Lo WD. Childhood hemorrhagic stroke: an important but understud-
ied problem. J Child Neurol. 2011;26:1174-1185.
 14. Ghotra SK, Johnson JA, Qiu W, Newton A, Rasmussen C, Yager JY. 
Age at stroke onset influences the clinical outcome and health-related 
quality of life in pediatric ischemic stroke survivors. Dev Med Child 
Neurol. 2015;57:1027-1034.
 15. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer 
Survivor Study: a National Cancer Institute–supported resource for 
outcome and intervention research. J Clin Oncol. 2009;27:2308-2318.
 16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health sur-
vey (SF-36). I. Conceptual framework and item selection. Med Care. 
1992;30:473-483.
 17. Kenzik KM, Huang IC, Brinkman TM, et al. The Childhood Cancer 
Survivor Study–Neurocognitive Questionnaire (CCSS-NCQ) revised: item 
response analysis and concurrent validity. Neuropsychology. 2015;29:31-44.
 18. Recklitis CJ, Parsons SK, Shih MC, Mertens A, Robison LL, Zeltzer 
L. Factor structure of the Brief Symptom Inventory-18 in adult survi-
vors of childhood cancer: results from the Childhood Cancer Survivor 
Study. Psychol Assess. 2006;18:22-32.
 19. Lackland DT, Roccella EJ, Deutsch AF, et al; American Heart 
Association Stroke Council; Council on Cardiovascular and Stroke 
Nursing; Council on Quality of Care and Outcomes Research; Council 
on Functional Genomics and Translational Biology. Factors influencing 
the decline in stroke mortality: a statement from the American Heart 
Association/American Stroke Association. Stroke. 2014;45:315-353.
 20. Kunin-Batson A, Kadan-Lottick N, Neglia JP. The contribution of neu-
rocognitive functioning to quality of life after childhood acute lympho-
blastic leukemia. Psychooncology. 2014;23:692-699.
 21. Netson KL, Ashford JM, Skinner T, et al. Executive dysfunction is asso-
ciated with poorer health-related quality of life in pediatric brain tumor 
survivors. J Neurooncol. 2016;128:313-321.
 22. Gunnes MW, Lie RT, Bjorge T, et al. Economic independence in survi-
vors of cancer diagnosed at a young age: a Norwegian national cohort 
study. Cancer. 2016;122:3873-3882.
 23. Wengenroth L, Sommer G, Schindler M, et al; Swiss Paediatric 
Oncology Group (SPOG). Income in adult survivors of childhood 
cancer. PLoS One. 2016;11:e0155546.
 24. Ellenberg L, Liu Q, Gioia G, et al. Neurocognitive status in long-term 
survivors of childhood CNS malignancies: a report from the Childhood 
Cancer Survivor Study. Neuropsychology. 2009;23:705-717.
 25. Robison LL, Hudson MM. Survivors of childhood and adolescent can-
cer: life-long risks and responsibilities. Nat Rev Cancer. 2014;14:61-70.
 26. King RB. Quality of life after stroke. Stroke. 1996;27:1467-1472.
 27. De Wit L, Theuns P, Dejaeger E, et al. Long-term impact of stroke 
on patients' health-related quality of life. Disabil Rehabil. 2017; 
39:1435-1440.
